Drug intelligence / Profile preview

JRF107

Development stage: Unknown
Lead developer: Shenzhen Jinruijiye Biotechnology
Modality: Small Molecules

Overview

JRF107 is a mitochondrial-targeted small molecule therapeutic developed by Shenzhen Jinruijiye Biotechnology for the treatment of psoriasis. The drug is designed using a proprietary mitochondrial targeting platform to address mitochondrial dysfunction, which is implicated in the pathogenesis of inflammatory skin diseases. By specifically localizing to the mitochondria, JRF107 aims to modulate cellular energy metabolism or oxidative stress pathways relevant to keratinocyte proliferation and inflammation. As of 2024, the compound has received Investigational New Drug (IND) clearance and is undergoing Phase 1 clinical evaluation.

Beyond the preview

Go deeper on JRF107.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JRF107.

Explore the full profile